Search

Your search keyword '"Burock, Susen"' showing total 69 results
Start Over Author "Burock, Susen"
69 results on '"Burock, Susen"'

51. Niclosamide a new chemotherapy agent? Pharmacokinetics of the potential anticancer drug in a patient cohort of the NIKOLO trial.

Author

Burock, Susen, primary, Daum, Severin, additional, Tröger, Hanno, additional, Kim, Theo Daniel, additional, Krüger, Sandrine, additional, Rieke, Damian Tobias, additional, Ochsenreither, Sebastian, additional, Welter, Kerstin, additional, Herrmann, Pia, additional, Sleegers, Arthur, additional, Walther, Wolfgang, additional, Keilholz, Ulrich, additional, and Stein, Ulrike, additional

Published
2018
Full Text
View/download PDF

52. Treatment of metastatic uveal melanoma (mUM) directed by a comprehensive molecular tumour analysis program (CMTA).

Author

Leyvraz, Serge, primary, Kessler, Thomas, additional, Schütte, Moritz, additional, Lamping, Mario, additional, Burock, Susen, additional, Ochsenreither, Sebastian, additional, Amstislavskiy, Vyacheslav, additional, Wierling, Christoph, additional, Jöhrens, Korinna, additional, Klauschen, Frederick, additional, Peuker, Caroline-Anna, additional, Kiecker, Felix, additional, Schäfer, Reinhold, additional, Lange, Bodo, additional, Lehrach, Hans, additional, Joussen, Antonia, additional, Rieke, Damian Tobias, additional, Klinghammer, Konrad Friedrich, additional, Keilholz, Ulrich, additional, and Yaspo, Marie-Laure, additional

Published
2018
Full Text
View/download PDF

53. Efficacy of a structured workflow for the interpretation of comprehensive genomic analysis data in clinical routine.

Author

Rieke, Damian Tobias, primary, Lamping, Mario, additional, Klauschen, Frederick, additional, Ochsenreither, Sebastian, additional, Schütte, Moritz, additional, Kessler, Thomas, additional, Klinghammer, Konrad Friedrich, additional, Jöhrens, Korinna, additional, Messerschmidt, Clemens, additional, Lenze, Dido, additional, Burock, Susen, additional, Ditzen, Doreen, additional, Schäfer, Reinhold, additional, Pavel, Marianne, additional, Tinhofer, Inge, additional, Sers, Christine, additional, Beule, Dieter, additional, Yaspo, Marie-Laure, additional, Leyvraz, Serge, additional, and Keilholz, Ulrich, additional

Published
2018
Full Text
View/download PDF

54. Abstract 2778: Combination of DNA mismatch repair status and MACC1 expression in patients with stage II colon cancer: The BIOGRID studies

Author

Rohr, Ulrich-Peter, primary, Herrmann, Pia, additional, Ilm, Katharina, additional, Zhang, Hai, additional, Lohmann, Sabine, additional, Reiser, Astrid, additional, Muranyi, Andrea, additional, Smith, Janice, additional, Burock, Susen, additional, Osterland, Marc, additional, Leith, Katherine, additional, Singh, Shalini, additional, Brunhoeber, Patrick, additional, Bowermaster, Rebecca, additional, Tie, Jeanne, additional, Christie, Michael, additional, Wong, Hui-Li, additional, Waring, Paul, additional, Shanmugam, Kandavel, additional, Gibbs, Peter, additional, and Stein, Ulrike S., additional

Published
2017
Full Text
View/download PDF

55. Collecting wisdom: Creating an evidence framework for personalized cancer therapy.

Author

Rieke, Damian Tobias, primary, Klinghammer, Konrad Friedrich, additional, Klauschen, Frederick, additional, Ochsenreither, Sebastian, additional, Burock, Susen, additional, Fusi, Alberto, additional, Sers, Christine, additional, Jöhrens, Korinna, additional, Hummel, Michael, additional, Materna, Verena Waltraut, additional, Tinhofer, Inge, additional, Dietel, Manfred, additional, Schäfer, Reinhold, additional, and Keilholz, Ulrich, additional

Published
2016
Full Text
View/download PDF

66. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society

Author

Siegel, Robert, primary, Burock, Susen, additional, Wernecke, Klaus-Dieter, additional, Kretzschmar, Albrecht, additional, Dietel, Manfred, additional, Loy, Volker, additional, Koswig, Stephan, additional, Budach, Volker, additional, and Schlag, Peter M, additional

Published
2009
Full Text
View/download PDF

67. Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer.

Author

Dahlmann, Mathias, Monks, Anne, Harris, Erik D., Kobelt, Dennis, Osterland, Marc, Khaireddine, Fadi, Herrmann, Pia, Kemmner, Wolfgang, Burock, Susen, Walther, Wolfgang, Shoemaker, Robert H., and Stein, Ulrike

Subjects
THERAPEUTIC use of antineoplastic agents, WNT proteins, CYTOSKELETAL proteins, METASTASIS, COLORECTAL cancer, CELLULAR signal transduction, GENE expression profiling, SURVIVAL analysis (Biometry), CELL lines, TUMOR markers
Abstract

Simple Summary: Aberrant Wnt/β-catenin signaling contributes to the development, progression, and metastasis of CRC, by altering target gene expression connected to cancer cell proliferation and motility. S100A4 is a Wnt/β-catenin target gene, which strongly enhances migration and invasion of CRC cells and thus CRC metastasis. Here, we report the transcriptional cross-regulation of S100A4 and the Wnt antagonist DKK1, in which the expression of S100A4 down-regulates DKK1 expression, sustaining activated Wnt signaling. S100A4 is an established prognostic biomarker for CRC patient survival, and the combination of S100A4 and DKK1 can be used to improve the prognosis of overall and metastasis-free survival. Metastasis is directly linked to colorectal cancer (CRC) patient survival. Wnt signaling through β-catenin plays a key role. Metastasis-inducing S100A4 is a Wnt/β-catenin target gene and a prognostic biomarker for CRC and other cancer types. We aimed to identify S100A4-dependent expression alterations to better understand CRC progression and metastasis for improved patient survival. S100A4-induced transcriptome arrays, confirmatory studies in isogenic CRC cell lines with defined β-catenin genotypes, and functional metastasis studies were performed. S100A4-regulated transcriptome examination revealed the transcriptional cross-regulation of metastasis-inducing S100A4 with Wnt pathway antagonist Dickkopf-1 (DKK1). S100A4 overexpression down-regulated DKK1, S100A4 knock-down increased DKK1. Recombinant DKK1 reduced S100A4 expression and S100A4-mediated cell migration. In xenografted mice, systemic S100A4-shRNA application increased intratumoral DKK1. The inverse correlation of S100A4 and DKK1 was confirmed in five independent publicly available CRC expression datasets. Combinatorial analysis of S100A4 and DKK1 in two additional independent CRC patient cohorts improved prognosis of overall and metastasis-free survival. The newly discovered transcriptional cross-regulation of Wnt target S100A4 and Wnt antagonist DKK1 is predominated by an S100A4-induced Wnt signaling feedback loop, increasing cell motility and metastasis risk. S100A4 and DKK1 combination improves the identification of CRC patients at high risk. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

68. Fighting Post-COVID and ME/CFS - development of curative therapies.

Author

Scheibenbogen C, Bellmann-Strobl JT, Heindrich C, Wittke K, Stein E, Franke C, Prüss H, Preßler H, Machule ML, Audebert H, Finke C, Zimmermann HG, Sawitzki B, Meisel C, Toelle M, Krueger A, Aschenbrenner AC, Schultze JL, Beyer MD, Ralser M, Mülleder M, Sander LE, Konietschke F, Paul F, Stojanov S, Bruckert L, Hedderich DM, Knolle F, Riemekasten G, Vehreschild MJGT, Cornely OA, Behrends U, and Burock S

Abstract

The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No curative therapies are available for ME/CFS or PCS. The mechanisms identified so far provide targets for therapeutic interventions. To accelerate the development of therapies, we propose evaluating drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic and outcome criteria and subgrouping patients based on a thorough clinical profiling including a comprehensive diagnostic and biomarker phenotyping., Competing Interests: The Charité Universitaetsmedizin Berlin holds a patent for the use of vericiguat in Post-COVID Syndrome. CS, JB-S, CH, KW, ES, CaF, HPru, HPre, M-LM, HA, ChF, HZ, BS, CM, MT, AK, MR, MM, LS, FKo, FP, LB, and SB are employed at Charité Universitaetsmedizin Berlin. CM was employed by Labor Berlin - Charité Vivantes GmbH. The remaining authors declare that the research was conducted in the absence of any comercial or financial relationships that could be construed as a potential conflict of interest. The Handling Editor NS declared a past collaboration with the Author CS., (Copyright © 2023 Scheibenbogen, Bellmann-Strobl, Heindrich, Wittke, Stein, Franke, Prüss, Preßler, Machule, Audebert, Finke, Zimmermann, Sawitzki, Meisel, Toelle, Krueger, Aschenbrenner, Schultze, Beyer, Ralser, Mülleder, Sander, Konietschke, Paul, Stojanov, Bruckert, Hedderich, Knolle, Riemekasten, Vehreschild, Cornely, Behrends and Burock.)

Published
2023
Full Text
View/download PDF

69. Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal swab.

Author

Lindner AK, Nikolai O, Rohardt C, Burock S, Hülso C, Bölke A, Gertler M, Krüger LJ, Gaeddert M, Tobian F, Lainati F, Seybold J, Jones TC, Hofmann J, Sacks JA, Mockenhaupt FP, and Denkinger CM

Subjects
Diagnostic Tests, Routine, Humans, Nasopharynx, Nose, COVID-19, SARS-CoV-2
Abstract

Competing Interests: Conflict of interest: A.K. Lindner has nothing to disclose. Conflict of interest: O. Nikolai has nothing to disclose. Conflict of interest: C. Rohardt has nothing to disclose. Conflict of interest: S. Burock has nothing to disclose. Conflict of interest: C. Hülso has nothing to disclose. Conflict of interest: A. Bölke has nothing to disclose. Conflict of interest: M. Gertler has nothing to disclose. Conflict of interest: L.J. Krüger has nothing to disclose. Conflict of interest: M. Gaeddert has nothing to disclose. Conflict of interest: F. Tobian has nothing to disclose. Conflict of interest: F. Lainati has nothing to disclose. Conflict of interest: J. Seybold has nothing to disclose. Conflict of interest: T.C. Jones has nothing to disclose. Conflict of interest: J. Hofmann has nothing to disclose. Conflict of interest: J.A. Sacks has nothing to disclose. Conflict of interest: F.P. Mockenhaupt has nothing to disclose. Conflict of interest: C.M. Denkinger has nothing to disclose.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results